Health 4 min read Apex Wire Culture Desk

FDA Misses Savara Drug Deadline: What It Means for Rare Lung Patients

The FDA will miss its Nov. 22 deadline on Savara's molgramostim for a rare lung disease with no approved treatment, sending shares down 16%.

Federal Office Building No. 8, the Food and Drug Administration's first modern headquarters, photographed in 1963

Image: Wikimedia Commons / U.S. Food and Drug Administration

WASHINGTON — The U.S. Food and Drug Administration told Savara on Friday it will miss its November 22 deadline to decide on molgramostim, an inhaled treatment for a rare lung disease with no approved drug therapy in the United States, the company said. The agency gave no revised date, and the review remains under way. Savara shares fell 16 percent premarket.

Molgramostim is inhaled recombinant human GM-CSF, a protein that helps lung immune cells clear the surfactant buildup behind autoimmune pulmonary alveolar proteinosis, or autoimmune PAP. Taken once daily through a nebulizer, it would be the first drug treatment for the condition, where patients now rely on a hospital procedure to wash out their lungs.

Key Takeaways

  • The FDA will miss its November 22, 2026, target date on Savara's molgramostim application.
  • Molgramostim treats autoimmune PAP, a rare disease with no FDA-approved drug; current care is whole-lung lavage under general anesthesia.
  • In the Phase 3 IMPALA-2 trial of 164 patients, lung gas transfer rose 9.8 points with molgramostim against 3.8 with placebo.
  • Savara shares fell 16 percent premarket on Friday.

What Is Autoimmune PAP and Why Molgramostim Matters

In autoimmune PAP, antibodies neutralize GM-CSF, a protein macrophages need to clear surfactant from the lungs' air sacs. Without it, surfactant builds up, gas transfer worsens, and patients develop shortness of breath, often with cough and fatigue. Over time the disease can scar the lungs and lead to a transplant.

No drug is approved for the condition. The main treatment is whole-lung lavage under general anesthesia, in which the lungs are repeatedly washed to remove the buildup. Molgramostim aims to restore the missing GM-CSF signal by inhalation, letting macrophages clear surfactant on their own.

What the IMPALA-2 Trial Showed for Molgramostim

The application rests on IMPALA-2, a global Phase 3 trial that randomly assigned 164 patients to molgramostim or placebo for 48 weeks. Results were published in the New England Journal of Medicine in August 2025. At week 24, DLCO rose 9.8 points with the drug and 3.8 with placebo, a difference of 6.0 points.

Filed in February 2026 under Priority Review, the application was extended by three months in April, moving the target date from August 22 to November 22, after Savara's answers counted as a major amendment. The company said then the regulator had raised no safety, effectiveness, or manufacturing concerns. Friday's notice means the target date will pass without a decision, and no new date has been set.

What Happens Next for Savara and Patients

Savara said it will keep working with the FDA to complete the review. "We appreciate the FDA's continued efforts on our application and look forward to working closely with the agency to complete its review," said Matt Pauls, the company's chair and chief executive. It gave no timetable for when the agency might act.

The November 22 date was a target action date under the Prescription Drug User Fee Act, not a statutory deadline. For patients, the delay means a longer wait for the first drug option where the only treatment is a hospital procedure. Approval would open Savara's first commercial market for the drug. Deal activity in biotech has stayed brisk, and US measles cases have passed 5,000 this year.

FactDetail
DrugMolgramostim, inhaled GM-CSF, 300 mcg daily
ConditionAutoimmune PAP
Target dateNov. 22, 2026 PDUFA date; none set
Phase 3 trialIMPALA-2, 164 patients, NEJM, Aug. 2025
Primary resultDLCO up 9.8 vs 3.8 points at week 24 (diff. 6.0, P<0.001)

Frequently Asked Questions

What is molgramostim, and what does it treat?

Molgramostim is inhaled GM-CSF, a protein that helps lung immune cells clear surfactant. It is being developed for autoimmune pulmonary alveolar proteinosis, a rare disease in which surfactant builds up and makes breathing harder. It is not approved by any regulator.

Why did the FDA miss the November 22 deadline for Savara's molgramostim?

The FDA told Savara on Friday it would not act by the November 22, 2026, target date. The agency said its review is ongoing and gave no revised date. The delay is not a rejection.

Is there an approved treatment for autoimmune pulmonary alveolar proteinosis?

No. There is no FDA-approved drug for autoimmune PAP. The main treatment is whole-lung lavage, an invasive procedure under general anesthesia that washes the lungs to remove surfactant buildup.

When will the FDA decide on Savara's molgramostim?

No revised date has been given. The FDA said only that its review remains under way.

Reported and fact-checked by our editorial desk against independent primary sources. Read our Editorial Policy.
Apex Wire Culture Desk

Entertainment, celebrity, sports, health and lifestyle.

More from the Apex Wire Culture Desk →

Share
✓ Link copied